---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-25-007075"
form_type: "8-K"
ticker: "ALGS"
cik: "0001799448"
company_name: "Aligos Therapeutics, Inc."
filed_at: "2025-11-06T23:59:59+00:00"
generated_at: "2026-05-16T23:55:38.848654+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Aligos Q3 net loss $31.5M; Phase 2 HBV study enrolling; cash $99.1M

## Summary
- Net loss of $31.5M in Q3 2025 vs $19.3M in Q3 2024; diluted EPS loss of $3.04.
- Cash, cash equivalents and investments $99.1M as of Sep 30, 2025; runway into Q3 2026.
- Phase 2 B-SUPREME trial of pevifoscorvir sodium (CAM-E) for chronic HBV enrolled first patient Aug 2025; interim data 2026.
- Preclinical combo data with ALG-055009 (THR-β) and incretin RAs showed synergistic weight loss; out-licensing discussions ongoing.
- R&D expenses rose to $23.9M (from $16.8M) driven by Phase 2 costs; G&A $5.2M (from $4.6M) due to legal.

## SEC filing metadata
- accession: 0001171843-25-007075
- form_type: 8-K
- ticker: ALGS
- cik: 0001799448
- company_name: Aligos Therapeutics, Inc.
- filed_at: 2025-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1799448/000117184325007075/0001171843-25-007075-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1799448/000117184325007075/f8k_110525.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-25-007075
- JSON: https://secwatch.observer/filing/0001171843-25-007075.json
- Plain text: https://secwatch.observer/filing/0001171843-25-007075.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.